DOAJ Open Access 2013

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus

Gagik Radikovich Galstyan

Abstrak

According to international consensus, metformin is acknowledged as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM). However, in most cases this treatment eventually requires intensification by supplementation with other hypoglycemic medications. The aim of the EDGE study (Effective Diabetes control with vildaGliptin and vildagliptin/mEtformin) was to assess the efficacy and safety of vildagliptin in comparison with other oral agents in routine management of patients with T2DM that has been poorly controlled by metformin monotherapy.

Topik & Kata Kunci

Nutritional diseases. Deficiency diseases

Penulis (1)

Gagik Radikovich Galstyan

Format Sitasi

APA MLA BibTeX

Galstyan, G.R. (2013). EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus. https://doi.org/10.14341/2072-0351-3761

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.14341/2072-0351-3761

Informasi Jurnal

Tahun Terbit: 2013
Sumber Database: DOAJ
DOI: 10.14341/2072-0351-3761
Akses: Open Access ✓